Isoginkgetin Inhibits RANKL-induced Osteoclastogenesis and Alleviates Bone Loss

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Osteoporosis is a bone disease characterized by high osteoclast activity, leading to bone loss and increased fracture risk.
• Understanding the molecular mechanisms inhibiting osteoclastogenesis is vital for developing effective osteoporosis treatments.

Purpose of the Study:

• To investigate the inhibitory effects and underlying mechanisms of Isoginkgetin (IGG) on osteoclastogenesis.
• To evaluate IGG's potential as a therapeutic agent for osteoporosis.

Main Methods:

• In vitro studies using bone marrow-derived macrophages (BMMs) to assess IGG's effects on osteoclast differentiation and function (TRAP analysis).
• In vivo osteoporosis model validation using Micro-CT and immunohistochemistry.
• Molecular analysis including RT-PCR and Western Blot to examine gene and protein expression in MAPK and NF-κB pathways, and oxidative stress markers.

Main Results:

• IGG demonstrated no cytotoxicity to BMMs at concentrations up to 10 μM.
• IGG significantly inhibited osteoclastogenesis, bone resorption, and the expression of key osteoclastogenic genes and proteins.
• IGG modulated the MAPK and NF-κB signaling pathways by inhibiting P38, ERK, and P65 phosphorylation and rescuing IκB-α degradation.
• IGG influenced oxidative stress markers (SOD-1, HO-1, catalase) and attenuated in vivo bone loss, improving trabecular bone parameters.

Conclusions:

• Isoginkgetin (IGG) effectively inhibits osteoclastogenesis and bone resorption through modulation of MAPK and NF-κB pathways and oxidative stress.
• IGG shows therapeutic potential for osteoporosis management by preserving bone density and reducing bone loss.